In addition, the company is currently conducting the ORIGIN Extend trial, which provides extended access to atacicept for participants from the ORIGIN Phase 2b or Phase 3 trials until commercial ...

Despite decades of research to develop effective treatments, the median survival for glioblastoma—the most common malignant primary brain tumor in adults—is just 15–18 months after diagnosis. One ...